Sara Secall

AmacaThera is a Toronto-based biotechnology company focused on developing and commercializing a unique, injectable hydrogel platform technology for a wide range of medical applications. Based on the research of world-renowned biomaterials scientist, Dr. Molly Shoichet, AmacaThera is commercializing combination products at the interface of biomaterials and pharmaceuticals. We have developed a platform technology which addresses the critical problem of sustaining therapeutic delivery of pharmacological agents for multiple disease areas.  Currently, we have developed a combination product for post-operative pain, which is our company's lead project.

CONNECTA Therapeutics S.L. is a biotechnology company that develops new treatments for CNS unmet medical needs. The company is initially focus on the clinical development of a new “first-in-class” molecule for the treatment of fragile X syndrome (FXS). FXS is the most common cause of hereditary intellectual disability and there are no therapeutic interventions currently available. The molecule was discovered after evaluating more than 30 molecular and cellular targets. The molecule has been proven, in in vitro tests and in vivo in animal models, to be an excellent neuroplasticity modulator with a great extension profile for other neurodevelopmental disorders (Rett syndrome, Down syndrome and autism spectrum disorders, among others).

Oxolife : enhancing female fertility Oxolife is a small-size clinical-stage company focused on female fertility. We are currently developing an innovative treatment (OXO-001) to enhance female fertility success through acting on peri/post implantatory process. Additionally, OXO-001 restores ovulation. OXO-001 is a first in class drug due to its mechanism of action, solving an unmet need, since no solution drug in the embryo implantation market segment is available today. Is envisioned that the first phase II clinical trial will be completed by 2023. OXO-001 is protected by three different patents under the same umbrella which cover all the possible uses for female fertility. Oxolife’s team is leaded by Agnès Arbat, Medical Doctor (Co-founder and CEO) and Ignasi Canals, Biochemist PhD (Co-founder and CSO). Both accumulate a wide experience in the Women’s health pharmaceutical industry. The team has been supported by Clinical and Scientific Opinion Leaders from prestigious centers in fertility and R&D.

Ability Pharmaceuticals is a clinical-stage biopharmaceutical company committed to develop first-in-class therapies that address unmet medical needs in the oncology space. AbilityPharmas is currently conducting, with ABTL0812, the most advanced asset, an international multi-center, double-blind, placebo-controlled phase 2b clinical trial in patients with metastatic pancreatic cancer to investigate ABTL0812 as first-lin therapy in combination with FOLFIRINOX chemotherapy. The study includes reference centers in Spain, France, United States and Israel. ABTL0812 has finished with very positive results a phase 2a clinical trial as first-line therapy in endometrial cancer and in squamous NSCLC in combination with paclitaxel and carboplatin. The study included leading institutions in Spain and France (Vall d’Hebron Institut d’Oncologia – VHIO, Institut Gustave Roussy, Centre Léon Bérard). ABTL0812 is the first cancer drug killing tumor cells through potent cytotoxic autophagy via inhibition of the Akt/mTOR axis, and the induction of robust endoplasmic reticular stress (ER Stress). Its unique mechanism of action was partially published at Clinical Cancer Research in December 2015 and fully characterized at Autophagy journal in May 2020. The compound has also immunomodulatory effects, turning "cold" immunogenic tumors into "hot" immunogenic. The compound is active as standalone treatment, it has synergy with chemotherapy, and it has synergy with anti PD1 therapies. The product has potential in several cancer types as first-line and maintenance therapy including lung, endometrial, pancreatic, breast, head and neck cancer, glioblastoma, cholangiocarcinoma and the pediatric cancer neuroblastoma. ABTL0812 has been granted Orphan Drug Designation for pancreatic cancer, neuroblastoma, and biliary tract cancer, by the US FDA and the European EMA. Development and marketing rights for Greater China granted to SciClone Pharmaceuticals, Inc.

Edesa Biotech, Inc. (Nasdaq: EDSA) is a clinical-stage biopharmaceutical company developing innovative ways to treat inflammatory and immune-related diseases. Our most advanced drug candidate is EB05 (paridiprubart), a monoclonal antibody developed for acute and chronic disease indications that involve dysregulated innate immune responses. Edesa is currently evaluating EB05 in a Phase 3 study as a potential treatment for Acute Respiratory Distress Syndrome (ARDS), a life-threatening form of respiratory failure. In addition, Edesa is developing an sPLA2 inhibitor, EB01, as a topical treatment for chronic Allergic Contact Dermatitis (ACD), a common occupational skin condition. The company has also received regulatory approval to conduct a Phase 2 trial its EB06 monoclonal antibody as a treatment for vitiligo, a life-altering autoimmune disease that causes skin to lose its color in patches. We also are planning a future Phase 2 study of paridiprubart for systemic sclerosis (scleroderma), an autoimmune rheumatic disorder that causes fibrosis (scarring/hardening) of skin and internal organs.

We are a Spanish CDMO specialized in decoding biologics production, from pDNA, mRNA to recombinant proteins. specialized in decoding biologics production, from DNA to proteins. We provide services from preclinical and clinical development up to GMP manufacturing, supporting our biopharma clients in getting their biological products to market as quickly as possible. At 53Biologics we always guarantee high quality standards and provide customer-centric services: 1) Cell Line Development and Cell Banking 2) Preclinical and Clinical Development 3) Contract Manufacturing: Production under GMP, GMP Like and non-GMP conditions. Contact us if you want more information!

aptaTargets is a clinical stage biopharmaceutical company focused in developing therapeutic applications based on aptamer technology. Our candidates are neuroprotectants and immunomodulators being developed from preclinical stages up to clinical proof-of-concept.

Clinical-stage biotech company founded by serial entrepreneurs and owned by private & institutional investors. Discovery and development of new chemical entities with strong IP and worldwide rights targeting big market indications in immunology and oncology. After successful proof-of-concept studies in early clinical phases, seeking license agreements with pharmaceutical companies for further clinical development and commercialization. ---- PIPELINE: ---- Two of Oncostellaes drug candidates have reached advanced development stages and are currently being evaluated in clinical studies in patients: OST-122 is a safe, non-systemic JAK inhibitor for the treatment of Ulcerative Colitis (Phase 2a), and OST-499 is a GR antagonist for the treatment of colon cancer and other solid tumors (Phase 1). Positive data on safety and efficacy that are expected to be available by the end of 2023 would provide outlicensing opportunities.

ZIP Solutions is a biotech startup, based at the Parc Científic de Barcelona (PCB). ZIP Solutions is part of the Bionaturis Group, offering a wide portfolio of products, services and technologies for the pharmaceutical and veterinary sectors. ZIP focuses its activities on the development of technologies, aiming at the creation of inteins-based biochemical tools (for Gene Therapy, ADC manufacture, protein conjugation and purification, protein and peptide cyclization, ...) as well as at the improvement of vaccines, both recombinant and DNA-based, for human and veterinary use. ZIP Solutions meets customer needs by increasing products value and biotechnological processes performance through ZIP’s innovative and proven technologies, complemented with the knowledge and skills of our team and co-developed in the context of collaborations with academic and industrial partners.

Agrasys is now Vivagran. Check our page on Linkedin.

AmacaThera is a Toronto-based biotechnology company focused on developing and commercializing a unique, injectable hydrogel platform technology for a wide range of medical applications. Based on the research of world-renowned biomaterials scientist, Dr. Molly Shoichet, AmacaThera is commercializing combination products at the interface of biomaterials and pharmaceuticals. We have developed a platform technology which addresses the critical problem of sustaining therapeutic delivery of pharmacological agents for multiple disease areas.  Currently, we have developed a combination product for post-operative pain, which is our company's lead project.

CONNECTA Therapeutics S.L. is a biotechnology company that develops new treatments for CNS unmet medical needs. The company is initially focus on the clinical development of a new “first-in-class” molecule for the treatment of fragile X syndrome (FXS). FXS is the most common cause of hereditary intellectual disability and there are no therapeutic interventions currently available. The molecule was discovered after evaluating more than 30 molecular and cellular targets. The molecule has been proven, in in vitro tests and in vivo in animal models, to be an excellent neuroplasticity modulator with a great extension profile for other neurodevelopmental disorders (Rett syndrome, Down syndrome and autism spectrum disorders, among others).

Oxolife : enhancing female fertility Oxolife is a small-size clinical-stage company focused on female fertility. We are currently developing an innovative treatment (OXO-001) to enhance female fertility success through acting on peri/post implantatory process. Additionally, OXO-001 restores ovulation. OXO-001 is a first in class drug due to its mechanism of action, solving an unmet need, since no solution drug in the embryo implantation market segment is available today. Is envisioned that the first phase II clinical trial will be completed by 2023. OXO-001 is protected by three different patents under the same umbrella which cover all the possible uses for female fertility. Oxolife’s team is leaded by Agnès Arbat, Medical Doctor (Co-founder and CEO) and Ignasi Canals, Biochemist PhD (Co-founder and CSO). Both accumulate a wide experience in the Women’s health pharmaceutical industry. The team has been supported by Clinical and Scientific Opinion Leaders from prestigious centers in fertility and R&D.

Ability Pharmaceuticals is a clinical-stage biopharmaceutical company committed to develop first-in-class therapies that address unmet medical needs in the oncology space. AbilityPharmas is currently conducting, with ABTL0812, the most advanced asset, an international multi-center, double-blind, placebo-controlled phase 2b clinical trial in patients with metastatic pancreatic cancer to investigate ABTL0812 as first-lin therapy in combination with FOLFIRINOX chemotherapy. The study includes reference centers in Spain, France, United States and Israel. ABTL0812 has finished with very positive results a phase 2a clinical trial as first-line therapy in endometrial cancer and in squamous NSCLC in combination with paclitaxel and carboplatin. The study included leading institutions in Spain and France (Vall d’Hebron Institut d’Oncologia – VHIO, Institut Gustave Roussy, Centre Léon Bérard). ABTL0812 is the first cancer drug killing tumor cells through potent cytotoxic autophagy via inhibition of the Akt/mTOR axis, and the induction of robust endoplasmic reticular stress (ER Stress). Its unique mechanism of action was partially published at Clinical Cancer Research in December 2015 and fully characterized at Autophagy journal in May 2020. The compound has also immunomodulatory effects, turning "cold" immunogenic tumors into "hot" immunogenic. The compound is active as standalone treatment, it has synergy with chemotherapy, and it has synergy with anti PD1 therapies. The product has potential in several cancer types as first-line and maintenance therapy including lung, endometrial, pancreatic, breast, head and neck cancer, glioblastoma, cholangiocarcinoma and the pediatric cancer neuroblastoma. ABTL0812 has been granted Orphan Drug Designation for pancreatic cancer, neuroblastoma, and biliary tract cancer, by the US FDA and the European EMA. Development and marketing rights for Greater China granted to SciClone Pharmaceuticals, Inc.

Edesa Biotech, Inc. (Nasdaq: EDSA) is a clinical-stage biopharmaceutical company developing innovative ways to treat inflammatory and immune-related diseases. Our most advanced drug candidate is EB05 (paridiprubart), a monoclonal antibody developed for acute and chronic disease indications that involve dysregulated innate immune responses. Edesa is currently evaluating EB05 in a Phase 3 study as a potential treatment for Acute Respiratory Distress Syndrome (ARDS), a life-threatening form of respiratory failure. In addition, Edesa is developing an sPLA2 inhibitor, EB01, as a topical treatment for chronic Allergic Contact Dermatitis (ACD), a common occupational skin condition. The company has also received regulatory approval to conduct a Phase 2 trial its EB06 monoclonal antibody as a treatment for vitiligo, a life-altering autoimmune disease that causes skin to lose its color in patches. We also are planning a future Phase 2 study of paridiprubart for systemic sclerosis (scleroderma), an autoimmune rheumatic disorder that causes fibrosis (scarring/hardening) of skin and internal organs.